ACC.17
Study patients were randomized to Pradaxa 150mg twice daily or warfarin (target INR 2-3) and remained on this treatment for the trial duration.
ACC.17
The researchers searched the U.S. Medicare database for NVAF patients 65 years of age and older who were newly prescribed one of the following medications: apixaban, dabigatran, rivaroxaban, or warfarin.
ACC.17
Jan Steffel, from the TIMI Study Group, Boston, MA, and colleagues presented on the safety of edoxaban in the context of atrial fibrillation (AF) ablation.